Halozyme Therapeutics HALO Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's cash provided by (used in) investing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's cash provided by (used in) investing activity, including discontinued operation?
- Halozyme Therapeutics (HALO) reported cash provided by (used in) investing activity, including discontinued operation of -$2.88M in Q1 2026.
- How has Halozyme Therapeutics's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
- Halozyme Therapeutics's cash provided by (used in) investing activity, including discontinued operation increased by 96.8% year-over-year, from -$90.42M to -$2.88M.
- What does cash provided by (used in) investing activity, including discontinued operation mean?
- The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.